Recce Pharmaceuticals on brink of development of new class of synthetic antibiotics

Highlights

  • Recce Pharmaceuticals are on the brink of the development of a new class of synthetic antibiotics, aimed at solving the problem of antibiotic resistance.
  • The new synthetic antibiotic differs from traditional antibiotics such as penicillin by not only fighting bacteria but completely eradicating it, avoiding ongoing mutations that lead to antibiotic resistance.
  • This completely new mechanism of action will create a powerful antibiotic with millions of active sites, as opposed to the maximum of around three sites from traditional antibiotics.

Recce Pharmaceuticals are on the brink of the development of a new class of synthetic antibiotics, aimed at solving the problem of antibiotic resistance. This development will be the first new class of antibiotics in 30 years and as Executive Director James Graham states, “This could be the biggest thing since penicillin.”

Recce Executive Director and co-inventor of the technology, Michele Dilizia spoke with BioWorld in regard to the synthetic nature of the antibiotics as opposed to being derived from natural sources such as penicillin. The benefit of a synthetic antibiotic is that it will fight all bacteria, including superbugs, but will remain resistant to the bacteria attempts to mutate and overcome its actions.

The synthetic antibiotics avoid the common pitfall of traditional antibiotics that operate on a lock-and-key mechanism. Once the antibiotic discovers, unlocks and destroys the bacteria, as soon as the bacteria mutates and evolves, the antibiotic ceases to work. Reece’s synthetic, universal antibiotic acts like a ‘master key’ to the bacterial membrane, whereby it adheres to the membrane, reacts with the protein and destroys the bacteria completely, leaving no further possibility of bacteria mutation.

This completely new mechanism of action will create a powerful antibiotic with millions of active sites, as opposed to the maximum of around three sites from traditional antibiotics.

 

About Recce Pharmaceuticals Ltd (ASX: RCE)

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad-spectrum activity designed to address the urgent global health problem of antibiotic-resistant superbugs.

Register Interest